Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Review
  • Published:

Pathogenesis and progression of monoclonal gammopathy of undetermined significance

Leukemia volume 22, pages 1651–1657 (2008)Cite this article

Abstract

In Caucasians, monoclonal gammopathy of undetermined significance (MGUS) is an age-related condition with prevalence as high as 3% in persons older than 50 years. Compared with whites, blacks have around two- and threefold higher prevalence rates of MGUS and multiple myeloma (MM), respectively. Risk of progression from MGUS to MM has been found to be very similar in whites and blacks. On average, the transformation rate to a malignant monoclonal gammopathy is 1% per year, with the mechanisms of progression likely related to bone marrow microenvironment and/or the cytokine network. Overall, the actuarial probability of progression at 25 years of follow-up is about 30%. However, when the competing causes of death are taken into account, the actual rate of progression is only 11%. The predictors of malignant transformation are the plasma cell mass (M-protein size and/or proportion of plasma cell in the bone marrow), IgA isotype, serum free light-chain ratio and ‘evolving’ type and ratio between phenotypically aberrant and normal bone marrow plasma cells. It is recommended to follow these patients, particularly those with high risk of progression, annually to detect MM before complications, such as renal failure or extensive skeletal, involvement occur.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kyle RA . Monoclonal gammopathy of undetermined significance: natural history in 241 patients. Am J Med 1978; 64: 814–826.

    Article  CAS  Google Scholar 

  2. International Myeloma Working Group. Criteria for classification of monoclonal gammopathies, multiple myeloma and related disorders: a report from the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

    Article  Google Scholar 

  3. Waldenström J . Studies on conditions associated with disturbed gammaglobulin formation (gammopathies). Harvey Lec 1960–1961; 56: 211–231.

    Google Scholar 

  4. Axelsson U . A 20-year follow-up study of 264 subjects with M-components. Acta Med Scand 1986; 219: 519–522.

    Article  CAS  PubMed  Google Scholar 

  5. Kyle RA . ‘Benign’ monoclonal gammopathy: a misnomer? JAMA 1984; 251: 1849–1854.

    Article  CAS  PubMed  Google Scholar 

  6. Kyle RA . ‘Benign’ monoclonal gammopathy—after 20–35 years of follow-up. Mayo Clin Proc 1993; 68: 26–36.

    Article  CAS  PubMed  Google Scholar 

  7. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton III LJ . Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859–866.

    Article  PubMed  Google Scholar 

  8. Bladé J . On the ‘significance’ of monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2004; 79: 855–856.

    Article  PubMed  Google Scholar 

  9. Bladé J . Monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 355: 2765–2770.

    Article  PubMed  Google Scholar 

  10. Axelson U, Bachmann R, Hallen J . Frequency of pathological proteins (M-components) in 5669 sera from an adult population. Acta Med Scand 1966; 179: 235–247.

    Article  Google Scholar 

  11. Saleun JP, Vicariot M, Deroff P, Morin JF . Monoclonal gammopathies in an adult population of Finistere, France. J Clin Pathol 1982; 35: 63–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Malacrida V, De Francesco D, Banfi G, Porta FA, Riches PG . Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. J Clin Pathol 1987; 40: 793–797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Aguzzi F, Bergami MR, Gasparro G, Bellotti V, Merlini G . Occurrence of monoclonal components in general practice: clinical implications. Eur J Haematol 1992; 48: 192–195.

    Article  CAS  PubMed  Google Scholar 

  14. Kyle RA, Finkelstein S, Elveback LR, Kurland LT . Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972; 40: 719–724.

    CAS  PubMed  Google Scholar 

  15. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369.

    Article  CAS  Google Scholar 

  16. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Landgren O, Katzmann JA, Hsing AW, Pfeiffer RM, Kyle RA, Yeboah ED et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82: 1468–1473.

    Article  PubMed  Google Scholar 

  18. Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M . Prevalence of monoclonal gammopathy of undetermined significance: study of 52 802 persons in Nagasaki city, Japan. Mayo Clin Proc 2007; 82: 1474–1479.

    Article  PubMed  Google Scholar 

  19. Kyle RA, Therneau TM, Melton III LJ, Dispenzieri A, Larson DR, Benson JT et al. Monoclonal gammopathy of undetermined significance: estimated incidence and duration prior to recognition. Blood 2007; 110: 79a, (Abstract 246).

    Google Scholar 

  20. Munshi NC . Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc 2007; 82: 1457–1459.

    Article  PubMed  Google Scholar 

  21. Kyle RA, Rajkumar SV . Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol Oncol Clin North Am 2007; 21: 1093–1114.

    Article  PubMed  Google Scholar 

  22. Kyle RA, Rajkumar SV . Monoclonal gammopathy of undetermined significance. Br J Haematol 2006; 134: 573–589.

    Article  CAS  PubMed  Google Scholar 

  23. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR . Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095–3098.

    Article  CAS  PubMed  Google Scholar 

  24. Eriksson M, Hallberg B . Familial occurrence of haematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 1992; 3: 63–67.

    Article  CAS  PubMed  Google Scholar 

  25. Bourguet CC, Grufferman S, Delzell E, DeLong E, Cohen HJ . Multiple myeloma and family history of cancer. A case–control study. Cancer 1985; 56: 2133–2139.

    Article  CAS  PubMed  Google Scholar 

  26. Brown LM, Linet MS, Greenberg RS, Silverman DT, Hayes RB, Swanson GM et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S.. Cancer 1999; 85: 2385–2390.

    Article  CAS  PubMed  Google Scholar 

  27. Cannon-Albright LA, Thomas A, Goldgar DE, Gholami K, Rowe K, Jacobsen M et al. Familiality of cancer in Utha. Cancer Res 1994; 54: 2378–2385.

    CAS  PubMed  Google Scholar 

  28. Munshi NC . Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies. Mayo Clin Proc 2007; 83: 1457–1459.

    Article  Google Scholar 

  29. Brown LM, Gridley G, Check D, Landgren O . Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among while and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 2008; 111: 3388–3394.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Landgren O, Rapkin JS, Mellemkjaer L, Gridley G, Goldin LR, Engels EA . Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia. Haematologica 2006; 91: 1697–1700.

    PubMed  Google Scholar 

  31. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.

    Article  Google Scholar 

  32. Bergsagel PL, Kuehl WM . The molecular biology of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds). Myeloma: Biology and Management, 3rd edn. Saunders: Philadelphia, 2004, pp 35–58.

    Google Scholar 

  33. Hallek M, Bergsagel PE, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Fonseca R . Cytogenetics in multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds). Myeloma: Biology and Management, 3rd edn. Saunders: Philadelphia, 2004, pp 67–81.

    Google Scholar 

  35. Brousseau M, Leleu X, Gerard J, Gastinne T, Godon A, Genevieve F et al. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients. Clin Cancer Res 2007; 13: 6026–6031.

    Article  CAS  PubMed  Google Scholar 

  36. Ocqueteau M, Orfao A, Almeida J, Bladé J, González M, García-Sanz R et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998; 152: 1655–1665.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P . CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008; 32: 379–382.

    Article  CAS  PubMed  Google Scholar 

  38. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood 2002; 99: 1745–1757.

    Article  CAS  PubMed  Google Scholar 

  39. Davies F, Dring AM, Li C, Rawstron AC, Shammas MA, O′Connor SM et al. Insights on the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003; 102: 4504–4511.

    Article  CAS  PubMed  Google Scholar 

  40. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109: 1692–1700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Chng WJ, Glebov O, Bergsagel PL, Kuehl WM . Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 571–596.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Hideshima T, Chauban D, Anderson KC . Cytokine, cytokine receptors, and signal transduction in human multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds). Myeloma: Biology and Management, 3rd edn. Saunders: Philadelphia, 2004, pp 59–65.

    Google Scholar 

  43. Rajkumar SV, Mesa R, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210–2216.

    PubMed  Google Scholar 

  44. Vacca A, Ribatti D, Roncalli L, Ranieri G, Serio G, Silvestris F et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508.

    Article  CAS  PubMed  Google Scholar 

  45. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA . Comparison of Il-1 beta expression by in situ hybridisation in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93: 300–305.

    CAS  PubMed  Google Scholar 

  46. Ogata A, Anderson KC . Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth. Leuk Res 1996; 20: 303–307.

    Article  CAS  PubMed  Google Scholar 

  47. Hideshima T, Chauban D, Schlossman R, Richardson P, Anderson C . The role of tumour necrosis factor alpha in the pathogenesis of human multiple myeloma: therapeutic implications. Oncogene 2001; 20: 4519–4527.

    Article  CAS  PubMed  Google Scholar 

  48. Bladé J, Filella X, Montoto S, Bosch F, Rosiñol L, Coca F et al. Interleukin-6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 117: 387–389.

    Article  PubMed  Google Scholar 

  49. Gregersen H, Pedersen G, Svendsen N, Thulstrup AM, Sorensen HT, Schonheyder HC . Multiple myeloma following an episode of community-acquired pneumococcal bacteraemia or meningitis. APMIS 2001; 109: 797–800.

    CAS  PubMed  Google Scholar 

  50. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101: 4998–5006.

    Article  CAS  PubMed  Google Scholar 

  51. Dispenzieri A . POEMS syndrome. Blood Rev 2007; 21: 285–299.

    Article  PubMed  Google Scholar 

  52. Pomann JJ, Rudner EJ . Scleromyxedema revisited. Int J Dermatol 2003; 42: 31–35.

    Article  PubMed  Google Scholar 

  53. Pasqualetti P, Festuccia V, Collacciani A, Casale R . The natural history of monoclonal gammopathy of undetermined significance at 5- to 20-year follow-up of 263 cases. Acta Haematol 1997; 97: 174–179.

    Article  CAS  PubMed  Google Scholar 

  54. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002; 20: 1625–1634.

    Article  PubMed  Google Scholar 

  55. Montoto S, Bladé J, Montserrat E . Monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 3087–3088.

    Google Scholar 

  56. Bladé J, López-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar JL et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992; 81: 391–394.

    Article  PubMed  Google Scholar 

  57. Baldini L, Guffanti A, Cesana BM, Colombi M, Chiorboli O, Damilano I et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996; 87: 912–918.

    CAS  PubMed  Google Scholar 

  58. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT . The impact of M-component type and immunoglobulin concentration on the risk of transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001; 86: 1172–1179.

    CAS  PubMed  Google Scholar 

  59. Rosiñol L, Cibeira MT, Montoto S, Rozman M, Esteve J, Filella X, Bladé J . Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in the M protein size. Mayo Clin Proc 2007; 82: 428–434.

    Article  PubMed  Google Scholar 

  60. Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–817.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoto S et al. Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003; 123: 631–636.

    Article  PubMed  Google Scholar 

  62. Rosiñol L, Carrió A, Bladé J, Queralt R, Aymerich M, Cibeira MT et al. Comparative genomic hybridization identifies two variants of smoldering multiple myeloma. Br J Haematol 2005; 130: 729–732.

    Article  PubMed  Google Scholar 

  63. Pérez-Persona E, Vidriales MV, Mateo G, García-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586–2592.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work has been supported in part by Grants 2003-REDG-136-O, FIS 05-240-O, RD 2006/0020/005 and CM07/107 from Fondo de Investigaciones Sanitarias de la Seguridad Social.

Author information

Authors and Affiliations

  1. Department of Hematology, Institut of Hematology and Oncology, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain

    J Bladé, L Rosiñol, M T Cibeira & C F de Larrea

Authors
  1. J Bladé
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Rosiñol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M T Cibeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C F de Larrea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Bladé.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bladé, J., Rosiñol, L., Cibeira, M. et al. Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22, 1651–1657 (2008). https://doi.org/10.1038/leu.2008.203

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.203

Keywords

This article is cited by

Search

Advanced search

Quick links